HBOT Conversations:
Laurie Anderson (Part 1)

Healing COVID with HBOT

Dr. Laurie is a Doctor of Pharmacy, and a graduate of the University of North Carolina – Chapel Hill (UNC-CH) School of Pharmacy and the Pharmacy Practice Residency Program at the University of California – San Francisco (UCSF).  Dr. Laurie spent many years in clinical practice, first as a neurosurgery clinical pharmacist at UCSF Medical Center and then as a general medicine and critical care clinical pharmacist at Duke Medical Center.  For the past 14 years Dr. Laurie has been working in industry, and is currently a safety scientist in early phase drug development, designing safety strategies for First Time in Human clinical trials.

Through her own journey navigating chronic illness, Dr. Laurie has explored and embraced many forms of alternative and non-traditional medicine to support her body for healing.  She has gravitated towards practitioners and modalities that treat the whole patient, with the mantra that tending to mind, body and spirit is the true key to lasting health.  Over the years, Dr. Laurie has discovered that this often leads to a ‘less is more’ approach. She discovered HBOT when she was struggling to heal from COVID, and now tells anyone who will listen about the power of oxygen and pressure.

Subscribe. Join the discussion. Share the hope.

Watch the Podcast

We are thrilled to have Dr. Laurie Anderson join us at the HBOT News Network. Dr. Laurie used Hyperbaric Oxygen Therapy to heal from a very serious COVID illness.

Dr. Laurie explains her background to the audience and that she received treatment in Raleigh, NC at the Extivita clinic. Her background is important and intriguing.  Dr. Laurie is a Pharmacist by training, a PharmD. While she has done some clinical work in the past, her passion lies in the safety of clinical studies. She focuses on early phase clinical study work, designing risk mitigation strategies for first time in human studies. Dr. Laurie explained that in her line of work she looks at the risk profile of the assets coming out, the design risk mitigation strategies, and then follows them in the clinic to track them to help ensure that they know what’s safe and what isn’t. Essentially, she is part of the team that helps determine if certain drugs are safe and effective.

di Girolamo explains that when he first started looking at hyperbarics, he was personally trying to understand if it was indeed safe and effective.  He found that it was, and was blown away that everyone wasn’t using it. This opened the door to Dr. Laurie telling her story of COVID healing with HBOT, and what led her to Extivita.

Dr. Laurie explains that she has a history of lyme diesease, and worked really hard not to get COVID in fear that she would struggle with complete healing.  She had been vaccinated and boostered, and when she did get COVID she became very ill. In addition to losing her sense of smell and taste, she had a relentless cough, really awful fatigue, and some shortness of breath that that just wasn’t improving.  She ended up on medical leave because she could not work, and when she started to reach the end of the medical leave she still was not improving. Dr. Laurie talked to the naturopath who had been following her for many years, and her naturopath suggested NAD infusions. Dr. Laurie had never heard of NAD infusions before, so she started to read about them and who does them locally in the Raleigh, NC area.  That’s when Dr. Laurie was introduced to the Extivita clinic.

Dr. Laurie came to Extivita to start NAD infusions, but was also encouraged to try Hyperbaric Oxygen Therapy to heal from COVID.  The clinic explained that they are seeing really great success using hyperbarics for COVID long-hauler patients. Dr. Laurie was hesitant due to her claustrophobia, but in the end she decided it was worth a try.  She educated herself on HBOT, and found that there wasn’t a reason why she shouldn’t do it.  She was desperate to heal from the COVID infection. So, she committed to 20 dives, 4 days a week and had phenomenal results; claiming significant improvement after only ten dives.

“I got to say, I was kind of blown away because I had been battling with no improvement for long enough to be concerned, and I came in and I think it was about maybe five or six dives in, and my taste and smell started returning. It was completely gone. And I started to see a change probably in maybe eight, nine or ten, that my cough started going away. I would say by 12 or 13 dives, I felt healed, I felt recovered and even better than I felt going in [the way I felt before getting COVID].”

Dr. Laurie exclaimed that she noticed a positive difference in her energy and sleep almost immediately.  She was more restful, and she said she pays close attention to those things because her history with chronic illness.

“I just could tell a difference. And in my energy, mainly. My energy level and my sleep really shifted, which was a real gift.”

Dr. Laurie even shared her story in an Extivita testimonal, hopeful that others can also discover the powerful combination of oxygen and pressure to heal from COVID.

 

Stay tuned next week for Part 2 of Dr. Laurie’s podcast. We will talk with her about some other benefits of HBOT, and we’ll pick her brain on clinical trials involving hyperbaric oxygen therapy.

 

Guests

Elena Schertz, NP

Dr. Laurie Anderson, Pharm.D.

Dr. Laurie is a Doctor of Pharmacy, and a graduate of the University of North Carolina – Chapel Hill (UNC-CH) School of Pharmacy and the Pharmacy Practice Residency Program at the University of California – San Francisco (UCSF).  Dr. Laurie spent many years in clinical practice, first as a neurosurgery clinical pharmacist at UCSF Medical Center and then as a general medicine and critical care clinical pharmacist at Duke Medical Center.  For the past 14 years Dr. Laurie has been working in industry, and is currently a safety scientist in early phase drug development, designing safety strategies for First Time in Human clinical trials.

Through her own journey navigating chronic illness, Dr. Laurie has explored and embraced many forms of alternative and non-traditional medicine to support her body for healing.  She has gravitated towards practitioners and modalities that treat the whole patient, with the mantra that tending to mind, body and spirit is the true key to lasting health.  Over the years, Dr. Laurie has discovered that this often leads to a ‘less is more’ approach.

When not working, Dr. Laurie is an avid gardener, ballroom dancer and traveler with her husband. Remaining curious and finding joy in every day are her super powers.

Subscribe Now, It’s Free!

[contact-form-7 id="65934" title="Subscribe"]

Recent HBOT News

Clinical Trial – HBOT Late Radiation Tissue Injury

Background: Radiotherapy is a common treatment for many malignancies. Radiation-related
complications developing months or years after radiation treatment are known as late
radiation tissue injury (LRTI) and are estimated to effect 5%-15% of all long-term survivors
who have received radiation.

Hyperbaric oxygen therapy (HBOT) is a well established treatment of LRTI. Most of the studies
evaluating effect of HBOT on LRTI are focused on survival, resolution of tissue damage and
improvement in LENT-SOMA scale. Very few studies have addressed effect of HBOT on pain in
LTRI. Krahn and colleagues were the first to report the analgesic effect of HBOT in 3 cases
of refractory pain in oncological patients with radiation soft tissue injury. Other studies
showed significant improvement in pain intensity in patients with breast cancer and pelvic
malignancies treated with HBOT for LTRI. In patients that had developed radiation- induced
brachial plexopathy, HBOT elicited an increase in warm pain thresholds and a reduction in
lymphoedema. A prospective case study of 16 patients with gynecological cancer found no
changes with respect to pain and depression outcomes. A trial in patients with radiation
induced proctopathy showed that 75% of patients with rectal pain had some improvement,
although none experienced a complete resolution of pain symptoms.

There are several mechanisms by which HBOT may elicit analgesic effects. There is a growing
body of evidence that HBOT’s analgesic effect related to nitric oxide metabolism and
endogenous opioid secretion. Furthermore, the inhibition of tumor necrosis factor alph
(TNF-α), the production of substance P, and the modulation of serotonergic pathways have all
demonstrated a modification in the pain response following HBOT. In animal studies HBOT
decreased allodynia and hyperalgesia in different models of neuropathic and inflammatory
pain. The long lasting antinociceptive effect of HBOT was found to be dose-dependent in
non-injured tissues.

In human studies, HBOT decreased pain and edema and improved function in patients suffering
from the complex regional pain syndrome, and improved pain scores and range of motion in
patients with idiopathic femoral head necrosis. Women suffering from interstitial cystitis
demonstrated a reduction in pelvic pain following weeks and months of HBOT treatment. In
patients suffering from idiopathic trigeminal neuralgia HBOT produced a rapid reduction in
symptoms and these effects were lasting for 6 months following treatment. HBOT was also found
to be an effective treatment for cluster headaches and migraines and alleviated muscle and
bone pains in patients with myofascial syndrome, fibromyalgia, and biphosphonate-related
osteonecrosis of the jaw.

Based on the evidence presented above and HBOT’s known analgesic effect in many conditions,
the investigators designed this study with the objective to evaluate if HBOT reduces pain,
improves depression and impacts on patients quality of life in patients suffering from late
radiation tissue injury.

Study Design: Prospective observational study (n=300). Patients that have had radiation
therapy for malignancy, developed late radiation injury and suffer from chronic pain.

Clinical Trial – HBOT in Fibromyalgia

Fibromyalgia (FM) is a chronic pain condition affecting several millions of Canadians.
Although the etiology and pathophysiology are poorly understood, there is a well-recognized
association between muscular pain in fibromyalgia and muscular hypoperfusion, hypoxia,
abnormal muscle metabolism and oxidative stress. Currently there is no cure for FM.
Pharmacological and non-pharmacological strategies are directed to control symptoms such as
pain, fatigue, non-restorative sleep and depression.

Hyperbaric oxygen therapy (HBOT) is an intermittent inhalation of 100% oxygen in a hyperbaric
chamber at a pressure higher than 1 absolute atmosphere. Physiological effect of HBOT is
based on a dramatic increase in the amount of dissolved oxygen carried by the blood which
enables oxygenation of ischemic areas with compromised circulation. It also activates
oxidant-antioxidant system, stimulates angio- and neurogenesis, modulates inflammatory
response, induces brain neuroplasticity and possesses analgesic effect.

While some interventions offer benefit for some patients, additional treatment alternatives
are needed for patients with FM in whom currently available options are either ineffective or
poorly tolerated. Given its physiological effect, HBOT could be considered as a potential
therapy for treatment of underlying muscular hypoxia, optimizing oxidant- antioxidant system
and controlling FM symptoms. The results from this study could therefore provide new
information supporting the basic science underling the pathophysiology of this disease and
stimulate novel therapies for patients suffering with FM.